


Technology: Denosumab is a human monoclonal antibody that binds to the RANKL protein on osteoclasts (cells that break down bone), inhibiting their formation, function, and survival, which regulates bone turnover by slowing bone resorption.

Denosumab Timeline



Spotlight On: Denosumab

September 30, 2026

	<i>Amgen v. Sandoz</i> 1:23-cv-02406 (D.N.J.) Settled	<i>Amgen v. Celltrion</i> 1:24-cv-06497 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Samsung Bioepis</i> 1:24-cv-08417 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Fresenius Kabi</i> 1:25-cv-01080 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Accord</i> 1:25-cv-01305 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Hikma</i> 1:25-cv-12152 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Shanghai Henlius Biotech</i> 1:25-cv-12160 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Biocon</i> 1:25-cv-13358 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Dr. Reddy's</i> 1:25-cv-17277 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	<i>Amgen v. Amneal</i> 1:25-cv-17278 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	<i>Amgen v. Alkem</i> 1:25-cv-17596 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing
7,364,736	x	x	x	x	x	x	x	x	x	x	x
7,427,659		x									
7,662,930					x						x
7,888,101			x	x	x	x	x	x	x	x	x
7,928,205	x	x	x	x	x	x	x	x	x	x	x
8,053,236		x		x	x	x	x	x	x	x	x
8,058,418	x		x	x	x	x		x	x	x	x
8,217,153							x				
8,247,210			x					x			x
8,460,896		x	x	x	x	x	x	x	x	x	x
8,680,248		x	x	x	x	x	x	x	x	x	x
9,012,178	x	x	x	x	x	x		x	x	x	x
9,133,493	x				x						
9,228,168	x	x		x	x	x	x	x	x	x	x
9,320,816	x	x	x	x	x					x	
9,328,134	x	x	x	x	x	x		x	x	x	x
9,359,435	x	x	x	x	x	x	x	x	x	x	x
9,371,554						x					
9,388,447					x						
9,481,901	x		x								
10,106,829		x	x	x	x	x	x	x	x	x	x
10,167,492	x	x	x	x	x	x		x	x	x	x


Spotlight On: Denosumab

September 30, 2026

	<i>Amgen v. Sandoz</i> 1:23-cv-02406 (D.N.J.) Settled	<i>Amgen v. Celltrion</i> 1:24-cv-06497 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Samsung Bioepis</i> 1:24-cv-08417 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Fresenius Kabi</i> 1:25-cv-01080 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Accord</i> 1:25-cv-01305 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Hikma</i> 1:25-cv-12152 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Shanghai Henlius Biotech</i> 1:25-cv-12160 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Biocon</i> 1:25-cv-13358 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Dr. Reddy's</i> 1:25-cv-17277 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	<i>Amgen v. Amneal</i> 1:25-cv-17278 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	<i>Amgen v. Alkem</i> 1:25-cv-17596 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing
10,227,627		x	x	x	x	x	x	x	x	x	x
10,421,987			x								
10,513,723	x	x	x	x	x	x	x	x	x	x	x
10,583,397	x	x	x	x	x	x	x	x	x	x	x
10,655,156			x	x	x		x	x		x	x
10,822,630	x	x	x	x	x	x		x	x	x	x
10,894,972	x	x	x	x	x	x	x	x	x	x	x
10,907,186			x					x			x
11,077,404	x	x		x	x	x	x	x	x	x	x
11,098,079	x	x	x	x	x	x	x	x	x	x	x
11,130,980	x	x	x	x	x	x		x	x	x	x
11,192,919						x	x	x	x		x
11,254,963	x	x	x	x	x	x	x	x	x	x	x
11,292,829			x								
11,299,760	x	x	x	x	x	x		x	x	x	x
11,319,568		x		x	x	x	x	x	x	x	x
11,384,378			x								
11,427,848			x								
11,434,514	x	x	x	x	x	x	x	x	x	x	x
11,459,595		x		x	x	x	x	x	x	x	x
11,486,883		x									
11,492,372						x	x	x	x		x

	<i>Amgen v. Sandoz</i> 1:23-cv-02406 (D.N.J.) Settled	<i>Amgen v. Celltrion</i> 1:24-cv-06497 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Samsung Bioepis</i> 1:24-cv-08417 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Fresenius Kabi</i> 1:25-cv-01080 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Accord</i> 1:25-cv-01305 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Hikma</i> 1:25-cv-12152 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Shanghai Henlius Biotech</i> 1:25-cv-12160 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Biocon</i> 1:25-cv-13358 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	<i>Amgen v. Dr. Reddy's</i> 1:25-cv-17277 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	<i>Amgen v. Amneal</i> 1:25-cv-17278 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	<i>Amgen v. Alkem</i> 1:25-cv-17596 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing
11,634,476			X								
11,685,772			X								
11,744,950			X	X							
11,786,866				X							
11,946,085		X	X	X	X	X	X	X	X	X	X
11,952,605		X		X	X	X	X	X	X	X	X
12,084,686				X	X	X	X	X	X	X	X


BPCIA and Denosumab Litigation Status



VENABLE LLP

*BPCIA Litigations includes Denosumab Litigations.

Denosumab Challenged Claim Types in Litigation*



*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints.

VENABLE LLP